EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
26 nov. 2023 23h37 HE
|
EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
PDAC announces 2024 Award Recipients
09 nov. 2023 10h00 HE
|
Prospectors & Developers Association of Canada (PDAC)
2024 PDAC Award Recipients: Osisko Mining - Wabun Tribal Council - O3 Mining - Lundin Group - Victoria Gold Corp.
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
31 oct. 2023 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two...
BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie in neuer Krebsindikation
19 oct. 2023 06h45 HE
|
BioNTech SE
Grundlage für Phase-2-Studienstart waren Daten einer klinischen Phase-1-Studie zur Untersuchung der Sicherheit und Verträglichkeit von Autogene Cevumeran (BNT122, RO7198457) in Kombination mit...
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
19 oct. 2023 06h45 HE
|
BioNTech SE
Initiation of Phase 2 builds on data from a Phase 1 clinical trial evaluating the safety and tolerability of autogene cevumeran (BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint...
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
27 sept. 2023 08h00 HE
|
Vaccinex, Inc.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
Government’s Critical Minerals Strategy Recognizes Canada’s Once-in-a-Generation Opportunity to Lead Low Carbon Transition
09 déc. 2022 13h30 HE
|
Prospectors & Developers Association of Canada (PDAC)
VANCOUVER, British Columbia, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The Prospectors & Developers Association of Canada (PDAC) is encouraged to see its recommendations on behalf of Canada’s mineral...
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
21 nov. 2022 09h00 HE
|
Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
16 nov. 2022 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
LICY FINAL DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action Filed by the Firm – LICY, PDAC
19 juin 2022 13h00 HE
|
The Rosen Law Firm PA
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp....